Structural damage progression in patients treated with methotrexate, baricitinib monotherapy or baricitinib + methotrexate based on their level of clinical response in the phase 3 ra-begin study

D. van der Heijde; P. Durez; G. Schett; E. Naredo; Mikkel Østergaard; G. Meszaros; N. Bello; I. De la Torre; P. Lopez-Romero; D. Schlichting; E. Nantz; R. Fleischmann

Structural damage progression in patients treated with methotrexate, baricitinib monotherapy or baricitinib + methotrexate based on their level of clinical response in the phase 3 ra-begin study

D. van der Heijde, P. Durez, G. Schett, E. Naredo, Mikkel Østergaard, G. Meszaros, N. Bello, I. De la Torre, P. Lopez-Romero, D. Schlichting, E. Nantz, R. Fleischmann

Department for Rheumatology and Spine Diseases

Original language	English
Journal	Annals of the Rheumatic Diseases
Volume	76
Issue number	Suppl 2
Pages (from-to)	233
Number of pages	1
ISSN	0003-4967
Publication status	Published - 2017

Cite this

van der Heijde, D., Durez, P., Schett, G., Naredo, E., Østergaard, M., Meszaros, G., Bello, N., De la Torre, I., Lopez-Romero, P., Schlichting, D., Nantz, E., & Fleischmann, R. (2017). Structural damage progression in patients treated with methotrexate, baricitinib monotherapy or baricitinib + methotrexate based on their level of clinical response in the phase 3 ra-begin study. Annals of the Rheumatic Diseases, 76(Suppl 2), 233.

Structural damage progression in patients treated with methotrexate, baricitinib monotherapy or baricitinib + methotrexate based on their level of clinical response in the phase 3 ra-begin study. / van der Heijde, D.; Durez, P.; Schett, G. et al.
In: Annals of the Rheumatic Diseases, Vol. 76, No. Suppl 2, 2017, p. 233.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

van der Heijde, D, Durez, P, Schett, G, Naredo, E, Østergaard, M, Meszaros, G, Bello, N, De la Torre, I, Lopez-Romero, P, Schlichting, D, Nantz, E & Fleischmann, R 2017, 'Structural damage progression in patients treated with methotrexate, baricitinib monotherapy or baricitinib + methotrexate based on their level of clinical response in the phase 3 ra-begin study', Annals of the Rheumatic Diseases, vol. 76, no. Suppl 2, pp. 233.

@article{063d9146b74943f99c209a415791f49f,

title = "Structural damage progression in patients treated with methotrexate, baricitinib monotherapy or baricitinib + methotrexate based on their level of clinical response in the phase 3 ra-begin study",

author = "\{van der Heijde\}, D. and P. Durez and G. Schett and E. Naredo and Mikkel {\O}stergaard and G. Meszaros and N. Bello and \{De la Torre\}, I. and P. Lopez-Romero and D. Schlichting and E. Nantz and R. Fleischmann",

note = "COPECARE",

year = "2017",

language = "English",

volume = "76",

pages = "233",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "Elsevier BV",

number = "Suppl 2",

}

TY - ABST

T1 - Structural damage progression in patients treated with methotrexate, baricitinib monotherapy or baricitinib + methotrexate based on their level of clinical response in the phase 3 ra-begin study

AU - van der Heijde, D.

AU - Durez, P.

AU - Schett, G.

AU - Naredo, E.

AU - Østergaard, Mikkel

AU - Meszaros, G.

AU - Bello, N.

AU - De la Torre, I.

AU - Lopez-Romero, P.

AU - Schlichting, D.

AU - Nantz, E.

AU - Fleischmann, R.

N1 - COPECARE

PY - 2017

Y1 - 2017

M3 - Conference abstract in journal

SN - 0003-4967

VL - 76

SP - 233

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - Suppl 2

ER -